August 2026– date –
-
World Economic Forum Names Exosome DDS and Personalized mRNA Cancer Vaccines as Top Emerging Technologies for 2026
World Economic Forum Global Overview The World Economic Forum's 'Top 10 Emerging Technologies of 2026' report details exosome drug delivery systems (DDS) and personalized mRNA cancer vaccines as key innovations. Exosome DDS leverages the... -
Exosome Drug Delivery and Personalized mRNA Cancer Vaccines Emerge as Top Tech Trends for 2026, Showing Promise in Clinical Trials
Today Tech Times Global Overview Today Tech Times reports that exosome drug delivery systems (DDS) and personalized mRNA cancer vaccines are leading technology trends for 2026. Exosome DDS is the focus of over 200 ongoing clinical trials... -
Beyond Vaccines: mRNA Technology Expands into Personalized Cancer, Protein Replacement, and Regenerative Medicine
Unknown Global Overview mRNA technology is rapidly expanding beyond vaccines into new medical applications, including personalized cancer vaccines, protein replacement therapies, and regenerative medicine. Ongoing research is actively fo... -
Navigating the Intricacies of Bispecific Antibody Design: Stability and Manufacturability Challenges Explored
Unknown (attributed to Prassanna Rao and Fränze Vorreiter) USA Overview Prassanna Rao and Fränze Vorreiter detail the design strategies and challenges of bispecific antibodies (BsAbs), which bind two distinct antigens simultaneously. BsA... -
Self-Amplifying RNA (saRNA) Gains Ground Over Conventional mRNA, Proving Superiority Across Diverse Therapeutics; First COVID-19 Vaccines Approved in Japan and EU
TriLink BioTechnologies USA Overview Self-amplifying RNA (saRNA) is gaining traction over conventional mRNA due to its ability to amplify transcripts inside cells, producing more protein per molecule and sustaining expression for days to... -
EMA Recommends Approval for New Hypercholesterolemia Drug Evlarco (Obicetrapib / Ezetimibe): A Combination of CETP Inhibitor and Cholesterol Absorption Inhibitor
EMA EU Overview On July 23, 2026, the EMA's CHMP adopted a positive opinion recommending marketing authorization for Evlarco (obicetrapib / ezetimibe). This oral medication is for the treatment of primary hypercholesterolemia or mixed dy... -
Penn Engineering Develops LNP-Based ‘One-Two Punch’ to Transform Oral Cancer Treatment: Co-Delivering p53 & Ciclopirox Significantly Reduces Tumor Burden in Resistant Models
Penn Engineering (University of Pennsylvania) USA Overview Researchers at Penn have developed a lipid nanoparticle (LNP) formulation to co-deliver two drugs, p53 and ciclopirox, for oral cancer treatment. This LNP platform aims to simult... -
PROTAC Research Shifts to Structural Design, Oral Bioavailability, and AI-Driven Approaches: Bibliometric Analysis Reveals Emerging Frontiers and Pivotal Trial Era
PubMed USA Overview A bibliometric analysis of 2,630 PROTAC publications from 2001-2025 reveals a shift from early E3 ligase recruitment research to current hotspots including structural basis, ternary complex design, EGFR-directed degra... -
FDA Approval of First PROTAC Vepdegestrant Raises New Challenges in Targeted Protein Degradation Patent Strategy
Elkington and Fife UK Overview The FDA approval of vepdegestrant, the first PROTAC, marks a significant milestone for targeted protein degradation (TPD), bringing complex intellectual property considerations to the forefront. The unique ... -
GLP-1 Receptor Agonist Research Rapidly Expanding Across MASLD–MASH–HCC Continuum: US Leads, China Shows Rapid Growth
Frontiers Switzerland Overview Research on GLP-1 Receptor Agonists (GLP-1RAs) in the context of MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), MASH (Metabolic Dysfunction-Associated Steatohepatitis), and HCC (Hepatocel...
